Ashton William 4

What Happened

• Ashton William, a director of Medicus Pharma Ltd. (MDCX), was granted a derivative award of 50,000 shares on June 3, 2026. The Form 4 reports an acquisition price of $0.00, indicating an option/award grant rather than a cash purchase or sale.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-04 (filed one day after the grant; within typical Form 4 timelines).
• Reported consideration: $0.00 (derivative award/option grant — no cash paid at grant).
• Vesting: The option was granted June 3, 2026, and is scheduled to vest quarterly in four equal installments over one year. (Footnote from filing.)
• Shares owned after the transaction: not specified in the provided filing excerpt — see the full Form 4 for total beneficial ownership.
• No indication in the excerpt of a 10b5-1 plan, tax-withholding sale, or immediate sale of underlying shares.

Context

• This was an option/award grant (derivative), not an exercise or open-market purchase — meaning no shares were sold or bought and no cash changed hands at the time of grant. Such time-based option awards are common as director compensation and do not, by themselves, signal intent to buy or sell stock.